Search

Your search keyword '"Santin, Alessandro D."' showing total 1,077 results
Start Over Author "Santin, Alessandro D."
1,077 results on '"Santin, Alessandro D."'

1. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2

Author

Mutlu, Levent, McNamara, Blair, Bellone, Stefania, Manavella, Diego D., Demirkiran, Cem, Greenman, Michelle, Verzosa, Miguel Skyler Z., Buza, Natalia, Hui, Pei, Hartwich, Tobias Max Philipp, Harold, Justin, Yang-Hartwich, Yang, Zipponi, Margherita, Altwerger, Gary, Ratner, Elena, Huang, Gloria S., Clark, Mitchell, Andikyan, Vaagn, Azodi, Masoud, Schwartz, Peter E., and Santin, Alessandro D.

Published
2024
Full Text
View/download PDF

3. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer

Author

Hill, Breana L, Graf, Ryon P, Shah, Kunal, Danziger, Natalie, Lin, Douglas I, Quintanilha, Julia, Li, Gerald, Haberberger, James, Ross, Jeffrey S, Santin, Alessandro D, Slomovitz, Brian, Elvin, Julia A, and Eskander, Ramez N

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Immunology, Genetics, Digestive Diseases, Cancer, Clinical Trials and Supportive Activities, Clinical Research, Evaluation of treatments and therapeutic interventions, 6.1 Pharmaceuticals, Good Health and Well Being, Female, Humans, Biomarkers, Tumor, Colorectal Neoplasms, DNA Mismatch Repair, Endometrial Neoplasms, High-Throughput Nucleotide Sequencing, Immune Checkpoint Inhibitors, Microsatellite Instability, endometrium, uterine cancer, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis
Abstract

ObjectiveMolecular profiling is developing to inform treatment in endometrial cancer. Using real world evidence, we sought to evaluate frontline immune checkpoint inhibitor vs chemotherapy effectiveness in advanced endometrial cancer, stratified by Tumor Mutational Burden (TMB) ≥10 mut/MB and microsatellite instability (MSI).MethodsPatients with advanced endometrial cancer in the US-based de-identified Flatiron Health-Foundation Medicine Clinico-Genomic Database were included. Data originated from patients treated between January 2011- March 2022 at 280 US clinics. Next-generation sequencing assays were performed via FoundationOne or FoundationOneCDx. Longitudinal clinical data were derived from electronic health records. Immune checkpoint inhibitor treatment included pembrolizumab, dostarlimab, and nivolumab monotherapies. Time to next treatment, time to treatment discontinuation, and overall survival were assessed with the log-rank test and Cox proportional hazard models with adjusted hazard ratios (aHR) for known prognostic factors. We used the Likelihood ratio test to compare biomarker performance.ResultsA total of 343 patients received chemotherapy and 28 received immune checkpoint inhibitor monotherapy as frontline treatment. Patients who received monotherapy were more likely to be stage III at diagnosis (immune checkpoint inhibitor: 54.6% vs chemotherapy: 15.0%; p

Published
2023

4. Correction: Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Author

Roque, Dana M., Siegel, Eric R., Buza, Natalia, Bellone, Stefania, Silasi, Dan-Arin, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Azodi, Masoud, Schwartz, Peter E., Rao, Gautam G., Reader, Jocelyn C., Hui, Pei, Tymon-Rosario, Joan R., Harold, Justin, Mauricio, Dennis, Zeybek, Burak, Menderes, Gulden, Altwerger, Gary, Ratner, Elena, and Santin, Alessandro D.

Published
2024
Full Text
View/download PDF

8. Quality of Life and Adverse Events: Prognostic Relationships in Long-Term Ovarian Cancer Survival

Author

Wenzel, Lari, Osann, Kathryn, McKinney, Chelsea, Cella, David, Fulci, Giulia, Scroggins, Mary J, Lankes, Heather A, Wang, Victoria, Nephew, Kenneth P, Maxwell, George L, Mok, Samuel C, Conrads, Thomas P, Miller, Austin, Mannel, Robert S, Gray, Heidi J, Hanjani, Parviz, Huh, Warner K, Spirtos, Nick, Leitao, Mario M, Glaser, Gretchen, Sharma, Sudarshan K, Santin, Alessandro D, Sperduto, Paul, Lele, Shashikant B, Burger, Robert A, Monk, Bradley J, and Birrer, Michael

Subjects
Cancer, Rehabilitation, Ovarian Cancer, Clinical Research, Rare Diseases, Management of diseases and conditions, 7.1 Individual care needs, Carcinoma, Ovarian Epithelial, Humans, Ovarian Neoplasms, Prognosis, Quality of Life, Survivors, Oncology and Carcinogenesis, Oncology & Carcinogenesis
Abstract

BackgroundThere is a critical need to identify patient characteristics associated with long-term ovarian cancer survival.MethodsQuality of life (QOL), measured by the Functional Assessment of Cancer Therapy-Ovarian-Trial Outcome Index (FACT-O-TOI), including physical, functional, and ovarian-specific subscales, was compared between long-term survivors (LTS) (8+ years) and short-term survivors (STS) (

Published
2021

12. Molecular determinants of clinical outcomes of pembrolizumab in recurrent ovarian cancer: Exploratory analysis of KEYNOTE-100

Author

Ledermann, Jonathan A., Shapira-Frommer, Ronnie, Santin, Alessandro D., Lisyanskaya, Alla S., Pignata, Sandro, Vergote, Ignace, Raspagliesi, Francesco, Sonke, Gabe S., Birrer, Michael, Provencher, Diane M., Sehouli, Jalid, Colombo, Nicoletta, González-Martín, Antonio, Oaknin, Ana, Ottevanger, P.B., Rudaitis, Vilius, Kobie, Julie, Nebozhyn, Michael, Edmondson, Mackenzie, Sun, Yuan, Cristescu, Razvan, Jelinic, Petar, Keefe, Stephen M., and Matulonis, Ursula A.

Published
2023
Full Text
View/download PDF

13. Health-Related Quality of Life in Patients With Advanced Endometrial Cancer Treated With Lenvatinib Plus Pembrolizumab or Treatment of Physician’s Choice

Author

Lorusso, Domenica, Colombo, Nicoletta, Herraez, Antonio Casado, Santin, Alessandro D., Colomba, Emeline, Miller, David Scott, Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally E., Ray-Coquard, Isabelle Laure, Shapira-Frommer, Ronnie, Kim, Yong Man, McCormack, Mary, Massaad, Rachid, Nguyen, Allison Martin, Zhao, Qi, McKenzie, Jodi, Prabhu, Vimalanand S., and Makker, Vicky

Published
2023
Full Text
View/download PDF

14. Contributors

Author

Aviki, Emeline, primary, Berkowitz, Ross S., additional, Broach, Vance, additional, Cantrell, Leigh A., additional, Chui, M. Herman, additional, Cliby, William, additional, Elias, Kevin M., additional, Hedrick Ellenson, Lora, additional, Fader, Amanda N., additional, Filho, Donato Callegaro, additional, Fleming, Nicole D., additional, Frumovitz, Michael, additional, Gershenson, David M., additional, Gordhandas, Sushmita, additional, Grisham, Rachel N., additional, Herbst, Arthur, additional, Hillman, R. Tyler, additional, Hinchcliff, Emily, additional, Hodgson, Anjelica, additional, Horowitz, Neil S., additional, Kertowidjojo, Elizabeth, additional, Kim, Sarah H., additional, Knisely, Anne, additional, Kurnit, Katherine C., additional, Lawson, Barrett, additional, Leitao, Mario M., additional, Levine, Douglas A., additional, Liu, Ying, additional, Long, Beverly, additional, Manning-Geist, Beryl, additional, Miao, Diana, additional, Mueller, Jennifer J., additional, Nagarajan, Priyadharsini, additional, O’Cearbhaill, Roisin E., additional, Peng, Katherine, additional, Ramalingam, Preetha, additional, Ratan, Ravin, additional, Salvo, Gloria, additional, Santin, Alessandro D., additional, Shafer, Aaron, additional, Soliman, Pamela, additional, Somasegar, Sahana, additional, Tymon-Rosario, Joan R., additional, Wright, Jason D., additional, Yamada, S. Diane, additional, and Zivanovic, Oliver, additional

Published
2023
Full Text
View/download PDF

16. Neratinib in patients with HER2-mutant, metastatic cervical cancer: Findings from the phase 2 SUMMIT basket trial

Author

Oaknin, Ana, Friedman, Claire F, Roman, Lynda D, D’Souza, Anishka, Brana, Irene, Bidard, François-Clement, Goldman, Jonathan, Alvarez, Edwin A, Boni, Valentina, ElNaggar, Adam C, Passalacqua, Rodolfo, T.M., Khanh, Santin, Alessandro D, Keyvanjah, Kiana, Xu, Feng, Eli, Lisa D, Lalani, Alshad S, Bryce, Richard P, Hyman, David M, Meric-Bernstam, Funda, Solit, David B, and Monk, Bradley J

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Oncology and Carcinogenesis, Cancer, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, 6.2 Cellular and gene therapies, Administration, Oral, Adult, Diarrhea, Female, Humans, Kaplan-Meier Estimate, Middle Aged, Mutation, Nausea, Neoplasm Recurrence, Local, Progression-Free Survival, Protein Kinase Inhibitors, Quinolines, Receptor, ErbB-2, Response Evaluation Criteria in Solid Tumors, Severity of Illness Index, Uterine Cervical Neoplasms, Cervical cancer, HER2 mutant, Neratinib, Clinical trial, Tyrosine kinase inhibitor, Receptor, erbB-2, Paediatrics and Reproductive Medicine, Oncology & Carcinogenesis, Clinical sciences, Oncology and carcinogenesis, Reproductive medicine
Abstract

ObjectiveSomatic HER2 mutations occur in ~5% of cervical cancers and are considered oncogenic and associated with poor prognosis. Neratinib, an irreversible pan-HER tyrosine kinase inhibitor, is active in multiple HER2-mutant cancers. SUMMIT is a phase II basket trial investigating the efficacy and safety of neratinib in solid tumors.MethodsPatients with HER2-mutant, persistent, metastatic/recurrent cervical cancer with disease progression after platinum-based treatment for advanced/recurrent disease received oral neratinib 240 mg/day with mandatory loperamide prophylaxis during cycle 1. The primary endpoint was confirmed objective response rate (ORR). Secondary endpoints included: response duration (DOR); clinical benefit rate (CBR); progression-free survival (PFS); overall survival (OS); safety.ResultsSixteen eligible patients were enrolled; 10 (62.5%) had endocervical adenocarcinoma. The most common HER2 mutation was S310F (63% of patients). Three of 12 RECIST-measurable patients had confirmed partial responses (ORR 25%; 95%CI 5.5-57.2%); 3 had stable disease ≥16 weeks (CBR 50%; 95%CI 21.1-78.9%). DOR for responders were 5.6, 5.9, and 12.3 months. Median PFS was 7.0 months (95%CI 0.7-18.3 months); median OS was 16.8 months (95%CI 4.1-NE months). Diarrhea (75%), nausea (44%), and decreased appetite (38%) were the most common adverse events. One patient (6%) reported grade 3 diarrhea. There were no grade 4 events, and no diarrhea-related treatment discontinuations.ConclusionsNeratinib monotherapy showed evidence of activity in heavily pretreated patients with HER2-mutant cervical cancer, with no new safety signals. Given the few effective options for cervical cancer after platinum-based therapy failure, neratinib warrants further investigation in this molecularly defined patient population.Trial registration numberNCT01953926 (ClinicalTrials.gov), 2013-002872-42 (EudraCT).

Published
2020

17. The Poly (ADP-ribose) polymerase inhibitor olaparib and pan-ErbB inhibitor neratinib are highly synergistic in HER2 overexpressing epithelial ovarian carcinoma in vitro and in vivo

Author

Han, Chanhee, McNamara, Blair, Bellone, Stefania, Harold, Justin, Manara, Paola, Hartwich, Tobias Max Philipp, Mutlu, Levent, Yang-Hartwich, Yang, Zipponi, Margherita, Demirkiran, Cem, Verzosa, Miguel Skyler Z., Altwerger, Gary, Ratner, Elena, Huang, Gloria S., Clark, Mitchell, Andikyan, Vaagn, Azodi, Masoud, Dottino, Peter R., Schwartz, Peter E., and Santin, Alessandro D.

Published
2023
Full Text
View/download PDF

18. Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate with topoisomerase I inhibitor payload, shows antitumor activity in uterine and ovarian carcinosarcoma with HER2/neu expression

Author

Mauricio, Dennis, Bellone, Stefania, Mutlu, Levent, McNamara, Blair, Manavella, Diego D., Demirkiran, Cem, Verzosa, Miguel Skyler Z., Buza, Natalia, Hui, Pei, Hartwich, Tobias Max Philipp, Harold, Justin, Yang-Hartwich, Yang, Zipponi, Margherita, Altwerger, Gary, Ratner, Elena, Huang, Gloria S., Clark, Mitchell, Andikyan, Vaagn, Azodi, Masoud, Schwartz, Peter E., and Santin, Alessandro D.

Published
2023
Full Text
View/download PDF

19. Randomised phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum-resistant or refractory ovarian/fallopian tube/primary peritoneal cancer

Author

Roque, Dana M., Siegel, Eric R., Buza, Natalia, Bellone, Stefania, Silasi, Dan-Arin, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Azodi, Masoud, Schwartz, Peter E., Rao, Gautam G., Reader, Jocelyn C., Hui, Pei, Tymon-Rosario, Joan R., Harold, Justin, Mauricio, Dennis, Zeybek, Burak, Menderes, Gulden, Altwerger, Gary, Ratner, Elena, and Santin, Alessandro D.

Published
2022
Full Text
View/download PDF

20. Randomized phase II trial of weekly ixabepilone ± biweekly bevacizumab for platinum- resistant or refractory ovarian / fallopian tube / primary peritoneal cancer (NCT03093155): updated survival and subgroup analyses

Author

Roque, Dana M., primary, Siegel, Eric R., additional, Buza, Natalia, additional, Bellone, Stefania, additional, Huang, Gloria S., additional, Altwerger, Gary, additional, Andikyan, Vaagn, additional, Clark, Mitchell, additional, Azodi, Masoud, additional, Schwartz, Peter E., additional, Rao, Gautam G., additional, Ratner, Elena, additional, and Santin, Alessandro D., additional

Published
2024
Full Text
View/download PDF

21. Supplementary Data S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

Author

Sheth, Sangini S., primary, Oh, Ji Eun, primary, Bellone, Stefania, primary, Siegel, Eric R., primary, Greenman, Michelle, primary, Mutlu, Levent, primary, McNamara, Blair, primary, Pathy, Shefali, primary, Clark, Mitchell, primary, Azodi, Masoud, primary, Altwerger, Gary, primary, Andikyan, Vaagn, primary, Huang, Gloria, primary, Ratner, Elena, primary, Kim, Daniel J., primary, Iwasaki, Akiko, primary, Levi, Angelique W., primary, Buza, Natalia, primary, Hui, Pei, primary, Flaherty, Sean, primary, Schwartz, Peter E., primary, and Santin, Alessandro D., primary

Published
2024
Full Text
View/download PDF

22. Supplementary Table S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

Author

Sheth, Sangini S., primary, Oh, Ji Eun, primary, Bellone, Stefania, primary, Siegel, Eric R., primary, Greenman, Michelle, primary, Mutlu, Levent, primary, McNamara, Blair, primary, Pathy, Shefali, primary, Clark, Mitchell, primary, Azodi, Masoud, primary, Altwerger, Gary, primary, Andikyan, Vaagn, primary, Huang, Gloria, primary, Ratner, Elena, primary, Kim, Daniel J., primary, Iwasaki, Akiko, primary, Levi, Angelique W., primary, Buza, Natalia, primary, Hui, Pei, primary, Flaherty, Sean, primary, Schwartz, Peter E., primary, and Santin, Alessandro D., primary

Published
2024
Full Text
View/download PDF

23. Supplementary Figure S1 from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

Author

Sheth, Sangini S., primary, Oh, Ji Eun, primary, Bellone, Stefania, primary, Siegel, Eric R., primary, Greenman, Michelle, primary, Mutlu, Levent, primary, McNamara, Blair, primary, Pathy, Shefali, primary, Clark, Mitchell, primary, Azodi, Masoud, primary, Altwerger, Gary, primary, Andikyan, Vaagn, primary, Huang, Gloria, primary, Ratner, Elena, primary, Kim, Daniel J., primary, Iwasaki, Akiko, primary, Levi, Angelique W., primary, Buza, Natalia, primary, Hui, Pei, primary, Flaherty, Sean, primary, Schwartz, Peter E., primary, and Santin, Alessandro D., primary

Published
2024
Full Text
View/download PDF

24. Data from Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

Author

Sheth, Sangini S., primary, Oh, Ji Eun, primary, Bellone, Stefania, primary, Siegel, Eric R., primary, Greenman, Michelle, primary, Mutlu, Levent, primary, McNamara, Blair, primary, Pathy, Shefali, primary, Clark, Mitchell, primary, Azodi, Masoud, primary, Altwerger, Gary, primary, Andikyan, Vaagn, primary, Huang, Gloria, primary, Ratner, Elena, primary, Kim, Daniel J., primary, Iwasaki, Akiko, primary, Levi, Angelique W., primary, Buza, Natalia, primary, Hui, Pei, primary, Flaherty, Sean, primary, Schwartz, Peter E., primary, and Santin, Alessandro D., primary

Published
2024
Full Text
View/download PDF

25. Integrated mutational landscape analysis of poorly differentiated high-grade neuroendocrine carcinoma of the uterine cervix

Author

Bellone, Stefania, primary, Jeong, Kyungjo, additional, Halle, Mari Kyllesø, additional, Krakstad, Camilla, additional, McNamara, Blair, additional, Greenman, Michelle, additional, Mutlu, Levent, additional, Demirkiran, Cem, additional, Hartwich, Tobias Max Philipp, additional, Yang-Hartwich, Yang, additional, Zipponi, Margherita, additional, Buza, Natalia, additional, Hui, Pei, additional, Raspagliesi, Francesco, additional, Lopez, Salvatore, additional, Paolini, Biagio, additional, Milione, Massimo, additional, Perrone, Emanuele, additional, Scambia, Giovanni, additional, Altwerger, Gary, additional, Ravaggi, Antonella, additional, Bignotti, Eliana, additional, Huang, Gloria S., additional, Andikyan, Vaagn, additional, Clark, Mitchell, additional, Ratner, Elena, additional, Azodi, Masoud, additional, Schwartz, Peter E., additional, Quick, Charles M., additional, Angioli, Roberto, additional, Terranova, Corrado, additional, Zaidi, Samir, additional, Nandi, Shuvro, additional, Alexandrov, Ludmil B., additional, Siegel, Eric R., additional, Choi, Jungmin, additional, Schlessinger, Joseph, additional, and Santin, Alessandro D., additional

Published
2024
Full Text
View/download PDF

26. Randomized Phase II Trial of Imiquimod with or without 9-Valent HPV Vaccine versus Observation in Patients with High-grade Pre-neoplastic Cervical Lesions (NCT02864147)

Author

Sheth, Sangini S., primary, Oh, Ji Eun, additional, Bellone, Stefania, additional, Siegel, Eric R., additional, Greenman, Michelle, additional, Mutlu, Levent, additional, McNamara, Blair, additional, Pathy, Shefali, additional, Clark, Mitchell, additional, Azodi, Masoud, additional, Altwerger, Gary, additional, Andikyan, Vaagn, additional, Huang, Gloria, additional, Ratner, Elena, additional, Kim, Daniel J., additional, Iwasaki, Akiko, additional, Levi, Angelique W., additional, Buza, Natalia, additional, Hui, Pei, additional, Flaherty, Sean, additional, Schwartz, Peter E., additional, and Santin, Alessandro D., additional

Published
2024
Full Text
View/download PDF

28. Integrated mutational landscape analysis of uterine leiomyosarcomas

Author

Choi, Jungmin, Manzano, Aranzazu, Dong, Weilai, Bellone, Stefania, Bonazzoli, Elena, Zammataro, Luca, Yao, Xiaotong, Deshpande, Aditya, Zaidi, Samir, Guglielmi, Adele, Gnutti, Barbara, Nagarkatti, Nupur, Tymon-Rosario, Joan R., Harold, Justin, Mauricio, Dennis, Zeybek, Burak, Menderes, Gulden, Altwerger, Gary, Jeong, Kyungjo, Zhao, Siming, Buza, Natalia, Hui, Pei, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Odicino, Franco, Pecorelli, Sergio, Ardighieri, Laura, Bilguvar, Kaya, Quick, Charles M., Silasi, Dan-Arin, Huang, Gloria S., Andikyan, Vaagn, Clark, Mitchell, Ratner, Elena, Azodi, Masoud, Imielinski, Marcin, Schwartz, Peter E., Alexandrov, Ludmil B., Lifton, Richard P., Schlessinger, Joseph, and Santin, Alessandro D.

Published
2021

31. Whole-exome sequencing of cervical carcinomas identifies activating ERBB2 and PIK3CA mutations as targets for combination therapy

Author

Zammataro, Luca, Lopez, Salvatore, Bellone, Stefania, Pettinella, Francesca, Bonazzoli, Elena, Perrone, Emanuele, Zhao, Siming, Menderes, Gulden, Altwerger, Gary, Han, Chanhee, Zeybek, Burak, Bianchi, Anna, Manzano, Aranzazu, Manara, Paola, Cocco, Emiliano, Buza, Natalia, Hui, Pei, Wong, Serena, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Odicino, Franco, Pecorelli, Sergio, Donzelli, Carla, Ardighieri, Laura, Angioli, Roberto, Raspagliesi, Francesco, Scambia, Giovanni, Choi, Jungmin, Dong, Weilai, Bilguvar, Kaya, Alexandrov, Ludmil B., Silasi, Dan-Arin, Huang, Gloria S., Ratner, Elena, Azodi, Masoud, Schwartz, Peter E., Pirazzoli, Valentina, Stiegler, Amy L., Boggon, Titus J., Lifton, Richard P., Schlessinger, Joseph, and Santin, Alessandro D.

Published
2019

35. Derangements in HUWE1/c-MYC pathway confer sensitivity to the BET bromodomain inhibitor GS-626510 in uterine cervical carcinoma

Author

Bonazzoli, Elena, Bellone, Stefania, Zammataro, Luca, Gnutti, Barbara, Guglielmi, Adele, Pelligra, Silvia, Nagarkatti, Nupur, Manara, Paola, Tymon-Rosario, Joan, Zeybek, Burak, Altwerger, Gary, Menderes, Gulden, Han, Chanhee, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S., Andikyan, Vaagn, Azodi, Masoud, Schwartz, Peter E., and Santin, Alessandro D.

Published
2020
Full Text
View/download PDF

37. In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma

Author

Han, Chanhee, Perrone, Emanuele, Zeybek, Burak, Bellone, Stefania, Tymon-Rosario, Joan, Altwerger, Gary, Menderes, Gulden, Feinberg, Jacqueline, Haines, Kaitlin, Muller Karger, Mariana Espinal, Bianchi, Anna, Zammataro, Luca, Manzano, Aranzazu, Bonazzoli, Elena, Manara, Paola, Buza, Natalia, Hui, Pei, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S., Azodi, Masoud, Schwartz, Peter E., Lopez, Salvatore, and Santin, Alessandro D.

Published
2020
Full Text
View/download PDF

39. Lenvatinib Plus Pembrolizumab for Advanced Endometrial Cancer

Author

Makker, Vicky, Colombo, Nicoletta, Herráez, Antonio Casado, Santin, Alessandro D., Colomba, Emeline, Miller, David S., Fujiwara, Keiichi, Pignata, Sandro, Baron-Hay, Sally, Ray-Coquard, Isabelle, Shapira-Frommer, Ronnie, Ushijima, Kimio, Sakata, Jun, Yonemori, Kan, Kim, Yong Man, Guerra, Eva M., Sanli, Ulus A., McCormack, Mary M., Smith, Alan D., Keefe, Stephen, Bird, Steven, Dutta, Lea, Orlowski, Robert J., and Lorusso, Domenica

Published
2022
Full Text
View/download PDF

41. #523 Initial efficacy and safety results from ENGOT-Ov60/GOG-3052/RAMP 201: a phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC)

Author

Banerjee, Susana N, primary, Ring, Kari L, additional, Niewenhuysen, Els Van, additional, Fabbro, Michel, additional, Aghajanian, Carol, additional, Oaknin, Ana, additional, Colombo, Nicoletta, additional, Santin, Alessandro D, additional, Clamp, Andrew R, additional, Moore, Kathleen N, additional, Rose, Peter G, additional, David M, O’Malley, additional, Chon, Hye Sook, additional, Salinas, Erin A, additional, Prendergast, Emily N, additional, Lustgarten, Stephanie, additional, Rodrigues, Manuel, additional, Gennigens, Christine, additional, Monk, Bradley J, additional, and Grisham, Rachel N, additional

Published
2023
Full Text
View/download PDF

42. Mutational landscape of primary, metastatic, and recurrent ovarian cancer reveals c-MYC gains as potential target for BET inhibitor

Author

Li, Charles, Bonazzoli, Elena, Bellone, Stefania, Choi, Jungmin, Dong, Weilai, Menderes, Gulden, Altwerger, Gary, Han, Chanhee, Manzano, Aranzazu, Bianchi, Anna, Pettinella, Francesca, Manara, Paola, Lopez, Salvatore, Yadav, Ghanshyam, Riccio, Francesco, Zammataro, Luca, Zeybek, Burak, Yang-Hartwich, Yang, Buza, Natalia, Hui, Pei, Wong, Serena, Ravaggi, Antonella, Bignotti, Eliana, Romani, Chiara, Todeschini, Paola, Zanotti, Laura, Zizioli, Valentina, Odicino, Franco, Pecorelli, Sergio, Ardighieri, Laura, Silasi, Dan-Arin, Litkouhi, Babak, Ratner, Elena, Azodi, Masoud, Huang, Gloria S., Schwartz, Peter E., Lifton, Richard P., Schlessinger, Joseph, and Santin, Alessandro D.

Published
2019

43. PARP-1 activity (PAR) determines the sensitivity of cervical cancer to olaparib

Author

Bianchi, Anna, Lopez, Salvatore, Altwerger, Gary, Bellone, Stefania, Bonazzoli, Elena, Zammataro, Luca, Manzano, Aranzazu, Manara, Paola, Perrone, Emanuele, Zeybek, Burak, Han, Chanhee, Menderes, Gulden, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S., Azodi, Masoud, Newberg, Justin Y., Pavlick, Dean C., Elvin, Julia, Frampton, Garrett M., Schwartz, Peter E., and Santin, Alessandro D.

Published
2019
Full Text
View/download PDF

45. PI3K oncogenic mutations mediate resistance to afatinib in HER2/neu overexpressing gynecological cancers

Author

Bonazzoli, Elena, Cocco, Emiliano, Lopez, Salvatore, Bellone, Stefania, Zammataro, Luca, Bianchi, Anna, Manzano, Aranzazu, Yadav, Ghanshyam, Manara, Paola, Perrone, Emanuele, Haines, Kaitlin, Espinal, Mariana, Dugan, Katherine, Menderes, Gulden, Altwerger, Gary, Han, Chanhee, Zeybek, Burak, Litkouhi, Babak, Ratner, Elena, Silasi, Dan-Arin, Huang, Gloria S., Azodi, Masoud, Schwartz, Peter E., and Santin, Alessandro D.

Published
2019
Full Text
View/download PDF

47. Sialylated Glycan Bindings from SARS-CoV-2 Spike Protein to Blood and Endothelial Cells Govern the Severe Morbidities of COVID-19.

Author

Scheim, David E., Vottero, Paola, Santin, Alessandro D., and Hirsh, Allen G.

Subjects
BLOOD proteins, BLOOD cells, POST-acute COVID-19 syndrome, ENDOTHELIAL cells, SARS-CoV-2, ERYTHROCYTES
Abstract

Consistent with well-established biochemical properties of coronaviruses, sialylated glycan attachments between SARS-CoV-2 spike protein (SP) and host cells are key to the virus's pathology. SARS-CoV-2 SP attaches to and aggregates red blood cells (RBCs), as shown in many pre-clinical and clinical studies, causing pulmonary and extrapulmonary microthrombi and hypoxia in severe COVID-19 patients. SARS-CoV-2 SP attachments to the heavily sialylated surfaces of platelets (which, like RBCs, have no ACE2) and endothelial cells (having minimal ACE2) compound this vascular damage. Notably, experimentally induced RBC aggregation in vivo causes the same key morbidities as for severe COVID-19, including microvascular occlusion, blood clots, hypoxia and myocarditis. Key risk factors for COVID-19 morbidity, including older age, diabetes and obesity, are all characterized by markedly increased propensity to RBC clumping. For mammalian species, the degree of clinical susceptibility to COVID-19 correlates to RBC aggregability with p = 0.033. Notably, of the five human betacoronaviruses, the two common cold strains express an enzyme that releases glycan attachments, while the deadly SARS, SARS-CoV-2 and MERS do not, although viral loads for COVID-19 and the two common cold infections are similar. These biochemical insights also explain the previously puzzling clinical efficacy of certain generics against COVID-19 and may support the development of future therapeutic strategies for COVID-19 and long COVID patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results